Maxygen (United States)
In research, Maxygen (United States) stands highest in Life Sciences (#4,513 of 14,347 worldwide), over all time.
- World rank, all time
- #10,822 of 42,892
- Rank in United States
- #2,389 of 8,685
- Research works
- 235 ▲ 23% vs 2013–17
- Citations
- 23k 98.1 per fractional work
- Top-10% rate
- 15.6% record average 16.5%
- Open access
- 31% world 28%
What is Maxygen (United States) known for in research?
The fields where it stands highest, over all time, ranked among every institution above the floor in each field.
| Field | World rank | Where that sits | Top-10% rate | Works |
|---|---|---|---|---|
| Life SciencesDomain | #4,513 of 14,347 | 37.1% | 145 |
Each strip is that field’s whole ranked pool, with the notch where Maxygen (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Dentistry, 8.9×. Every wedge is a field page.
Who are the top researchers at Maxygen (United States)?
Ranked on the composite score, Gerald McMahon and Robert A. Blake lead among researchers whose main affiliation is Maxygen (United States).
- 1 Gerald McMahon United States · #201,210 worldwide 323 citations · 18 works
- 2 Robert A. Blake United States · #404,242 worldwide 192 citations · 15 works
Which keywords describe research at Maxygen (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Cancer, Glycosylation, Cancer Therapy, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors and Autoimmunity.
- Plant Molecular Farming
- Cell Migration
- Natural Killer Cells
- Monoclonal Antibody
- Dendritic Cells
- Immunity
- CD4+CD25+
- VEGF
- Mutation
- Genome Engineering
- Chemotherapy
- Metabolism
- Stem Cells
- Cell Signaling
- Tumor Microenvironment
- Transcriptional Regulation
- Fc Receptors
- Therapeutic Antibodies
- Cancer Therapy
- Glycosylation
- Cancer
- Inflammation
- Monoclonal Antibodies
- Antibody Engineering
- Autoimmunity
- Cancer Immunotherapy
- Antigen Presentation
- Angiogenesis
- Innate Immunity
- Vascular Endothelial Growth Factor
- Immune Response
- RNA-Guided
- TGF-ß
- endothelial progenitor cells
- Foxp3
- Biopharmaceuticals
- Tumor Antigen
- NK Cell Recognition
- Recombinant Proteins
- Extracellular Matrix
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Cancer26▲ 7.8×26 topics
- Glycosylation14▲ 28×3 topics
- Inflammation12▲ 2.1×23 topics
- Cancer Therapy12▲ 7.8×8 topics
- Monoclonal Antibodies10▲ 29×3 topics
- Therapeutic Antibodies9▲ 31×2 topics
- Antibody Engineering9▲ 39×1 topic
- Fc Receptors9▲ 39×1 topic
- Autoimmunity9▲ 18×3 topics
- Transcriptional Regulation7▲ 12×7 topics
- Cancer Immunotherapy7▲ 22×3 topics
- Tumor Microenvironment7▲ 8.6×5 topics
- Antigen Presentation7▲ 30×2 topics
- Cell Signaling7▲ 8.8×8 topics
- Angiogenesis7▲ 7.2×8 topics
- Stem Cells7▲ 9.8×9 topics
- Innate Immunity7▲ 8.1×7 topics
- Metabolism7▲ 4.4×14 topics
- Vascular Endothelial Growth Factor7▲ 28×2 topics
- Chemotherapy6▲ 3.9×8 topics
- Immune Response6▲ 4.5×6 topics
- Genome Engineering6▲ 47×1 topic
- RNA-Guided6▲ 47×1 topic
- Mutation6▲ 17×4 topics
- TGF-ß6▲ 16×3 topics
- VEGF6▲ 77×1 topic
- endothelial progenitor cells6▲ 77×1 topic
- CD4+CD25+6▲ 34×1 topic
- Foxp36▲ 34×1 topic
- Immunity6▲ 7.5×3 topics
- Biopharmaceuticals6▲ 34×3 topics
- Dendritic Cells5▲ 20×1 topic
- Tumor Antigen5▲ 28×1 topic
- Monoclonal Antibody5▲ 32×2 topics
- NK Cell Recognition5▲ 22×1 topic
- Natural Killer Cells5▲ 22×1 topic
- Recombinant Proteins5▲ 41×2 topics
- Cell Migration5▲ 24×2 topics
- Extracellular Matrix5▲ 8.4×5 topics
- Plant Molecular Farming5▲ 83×1 topic
Which research topics does Maxygen (United States) publish most on?
By volume in 2022–2025: Muscle Physiology and Disorders, E-Government and Public Services, Tissue Engineering and Regenerative Medicine and Cancer Immunotherapy and Biomarkers.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Muscle Physiology and Disorders Molecular Biology 1 works
- 2 E-Government and Public Services Political Science and International Relations 1 works
- 3 Tissue Engineering and Regenerative Medicine Surgery 1 works
- 4 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 5 CAR-T cell therapy research Oncology 1 works
- 6 Immunotherapy and Immune Responses Immunology 0 works
- 7 Immune Cell Function and Interaction Immunology 0 works
- 8 Genetic Neurodegenerative Diseases Cellular and Molecular Neuroscience 0 works
- 9 Cancer Genomics and Diagnostics Cancer Research 0 works
- 10 Microbial Inactivation Methods Biotechnology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Maxygen (United States)'s research output changed?
Output in 2018–2022 was 23% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Redwood City
- Heron Therapeutics (United States)
- Chan Zuckerberg Initiative (United States)
- Emergency University
- Guardant (United States)
- Box (United States)
- OncoMed (United States)
- Genomic Health (United States)
- Ubiquitous Energy (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.